[Courtesy of Kwangdong]
SEOUL -- Kwang Dong Pharmaceutical, a human healthcare provider in South Korea, has forged a strategic partnership with Oxford Cancer Biomarkers (OCB), a spinout from Oxford University that is developing tests to allow medicines to be personalized for cancer patients.
Kwang Dong said Monday that it would participate in OCB as a strategic investor. OCB develops predictive companion biomarker diagnostic products to guide the identification and selection of cancer patients that respond favorably to emergent cancer drugs. The amount of investment and other details were not disclosed.
Through the partnership, the South Korean company hopes to secure an opportunity for the development of products that can predict the outcome of diseases with artificial intelligence or provide information about if anti-cancer drugs are toxic through genetic testing.
reporter
Lim Chang-won
cwlim34@ajunews.com
